Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.
- Formal TGA lodgement for CONNEQT Pulse device completed
- Device already FDA-cleared in the United States
- Market agreement finalized with manufacturing partner Andon
- TGA approval process expected to take 3 to 6 months
- Positions Cardiex for entry into Australian cardiovascular device market
Regulatory Milestone Achieved
Cardiex Limited (ASX:CDX) has taken a significant step forward in its global expansion strategy by lodging its CONNEQT Pulse device with the Australian Therapeutics Goods Administration (TGA). This formal application seeks inclusion of the device in the Australian Register of Therapeutic Goods (ARTG), a prerequisite for commercial distribution within Australia.
The CONNEQT Pulse device, which has already secured FDA clearance in the United States, represents Cardiex’s flagship cardiovascular technology designed to improve vascular health outcomes. The TGA lodgement follows a recently finalized market agreement with manufacturing partner Andon, which will support the regulatory and production requirements necessary for the Australian market.
Strategic Implications for Cardiex
CEO Craig Cooper highlighted the importance of this milestone, emphasizing the company’s commitment to establishing a strong global footprint for the CONNEQT brand. With regulatory approval in two major markets, Cardiex is positioning itself to capitalize on growing demand for innovative cardiovascular health solutions, particularly in regions with aging populations and rising chronic disease prevalence.
The TGA registration process is anticipated to take between three and six months, a timeline that suggests Cardiex could be poised for commercial launch in Australia by late 2025 or early 2026. This timing aligns with broader industry trends favoring remote and home-based health monitoring technologies, potentially offering Cardiex a competitive edge.
Market and Investor Outlook
Investors will be watching closely as Cardiex navigates this regulatory pathway. Successful ARTG inclusion would not only validate the device’s safety and efficacy under Australian standards but also open a new revenue stream in a market with significant cardiovascular health challenges. The partnership with Andon further strengthens the company’s operational capabilities, reducing execution risk associated with manufacturing and supply chain logistics.
While the announcement does not provide specific financial guidance, the regulatory progress signals positive momentum for Cardiex’s growth trajectory. Shareholders can expect ongoing updates as the TGA review advances and as Cardiex pursues additional commercial milestones.
Bottom Line?
Cardiex’s TGA lodgement sets the stage for Australian market entry, with approval timing and commercial uptake now the key focus.
Questions in the middle?
- Will Cardiex secure TGA approval within the anticipated 3-6 month window?
- How will the partnership with Andon influence manufacturing scale and costs?
- What is the competitive landscape for cardiovascular devices in Australia, and how will CONNEQT Pulse differentiate?